Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07425782 | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | recruiting | Phase 2 | 216 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07672262 | VA Consolidation in Intermediate-Risk AML | recruiting | Phase 2 | 226 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 43 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07548710 | Study of SA+X in the Treatment of Newly Diagnosed AML | recruiting | Phase 2 | 205 | Ruijin HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07392970 | Motixafortide for MRD Sensitization in AML | recruiting | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Incyte Biosciences International SàrlINDUSTRY | 7 | Jul 23, 2026 | clinicaltrials |
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | recruiting | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07008638 | Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 32 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | recruiting | Phase 2 | 102 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents(TAGALONG) | recruiting | Phase 2 | 53 | Joshua ZeidnerOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | recruiting | Phase 2 | 28 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04050280 | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | recruiting | Phase 2 | 39 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)(BMT-13) | recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03670966 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | recruiting | Phase 1 / Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06707493 | Ivosidenib as Post-HSCT Maintenance for AML | recruiting | Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04047641 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03586609 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07623616 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | recruiting | Phase 2 | 6 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03589729 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01409161 | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | recruiting | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | recruiting | Phase 2 | 508 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 84 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | recruiting | Phase 1 / Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05133882 | A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML | recruiting | Phase 1 / Phase 2 | 133 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | recruiting | Phase 1 / Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | recruiting | Phase 2 / Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML(IDH1-AML-2024) | recruiting | Phase 1 / Phase 2 | 23 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML(DAV-AML-2024) | recruiting | Phase 2 | 380 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | recruiting | Phase 2 | 160 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04977180 | Cardioprotection in AML(AML 001) | recruiting | Phase 2 | 70 | University of VirginiaOTHER | 1 | May 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials